Envoy Medical, Inc. Class A (COCH) Dividend History

Company News

• EdgarAgents Debuts EA34 Plugin at Centri Capital Conference to Simplify and Expedite Financial Filing Process for Mid-to-Microcap Companies

  EdgarAgents, a leading provider of SEC compliance filing solutions, has launched EA34 Plugin, a technology-enabled platform that simplifies the financial reporting process for mid-to-microcap companies. The plugin eliminates the complex XBRL tagging process and enables intuitive collaboration through Microsoft 365 apps.

  GlobeNewswire Inc.
• Envoy Medical Receives FDA Approval To Initiate Pivotal Clinical Study for Breakthrough Hearing Device

  Envoy Medical received FDA approval to initiate a pivotal clinical study for its Acclaim Fully Implanted Cochlear Implant, a breakthrough hearing device that leverages the natural anatomy of the ear to capture sound.

  GlobeNewswire Inc.
• Envoy Medical Announces Inclusion in the MSCI USA Micro Cap Index

  WHITE BEAR LAKE, MN, June 06, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. (“Envoy Medical”) (Nasdaq: COCH), a revolutionary hearing health company focused on fully implanted hearing systems, announces that MSCI has selected the Company’s shares for inclusion in its MSCI USA Micro Cap Index.  The inclusion became effective at the close of market on Friday, May 31, 2024.  The MSCI USA Micro Cap Index is designed to measure the performance of the micro cap segment of the U.S. equity market and is comprised of over 1,100 constituents with an average market cap of $122 million at April 30, 2024.  A wide range of microcap ETFs follow this benchmark and may reweight their holdings over the coming weeks for changes that occurred in this Index effective as of May 31.

  GlobeNewswire Inc.
• Envoy Medical Reports First Quarter 2024 Results

  The Company, a current leader in fully implanted hearing devices, continues to steadily march towards its ambition of disrupting the existing cochlear implant industry with its “breakthrough” fully implanted cochlear implant.

  GlobeNewswire Inc.
• Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session

  Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms. Ultragenyx Pharmaceutical shares dipped 9.4% to $42.46 on Monday. Here are some other stocks moving in today's mid-day session. Gainers Soligenix, Inc. (NASDAQ: SNGX) shares surged 71.5% to $0.6679 after the company announced that it was granted orphan drug designation to the active ingredient in MarVax for the prevention and post-exposure prophylaxis against MARV infection by the FDA. Longeveron Inc. (NASDAQ: LGVN) surged 54% to $2.6350 following insider buys from multiple company executives. SuperCom Ltd. (NASDAQ: SPCB) shares gained 39.4% to $0.3849 after jumping around 18% on Friday. Piedmont Lithium Inc. (NYSE: PLL) shares gained 32.1% to $16.75 following a 5% decline on Friday. Snap One Holdings Corp. (NASDAQ: SNPO) surged 31.6% to $10.71 after the company announced that it will be acquired by Resideo Technologies. Organovo Holdings, Inc. (NASDAQ: ONVO) shares surged 30.9% to $1.32 after the company announced Phase 2 results for FXR314. Study results demonstrated statistically significant reduction in liver fat content from baseline in patients receiving FXR314 compared to placebo. Kuke Music Holding Limited (NASDAQ: KUKE) jumped 27% to $2.7650. HUB Cyber Security Ltd. (NASDAQ: HUBC) gained 24% to $1.61 after gaining over 11% on Friday. Edgio, Inc. (NASDAQ: EGIO) gained 24% to $22.18. Kaival Brands Innovations Group, Inc. (NASDAQ: KAVL) ...

  Benzinga

  Featured Companies: ADIL AEYE BB BHVN CENX CYN DXYZ EXTR HUBC IMCC INFA KAVL LGVN LOCL MNDR MPW NMRA NXPL OCX PLL PMN PROK PSNY QTTB RARE RENT SES SNGX SPCB SPWR SRFM SWVL VERU